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We experienced a case of immunoglobulin E (IgE) mediated anaphylaxis to levo-
dropropizine. The patient was an 18-year old Korean woman. After taking the 
common cold medication including acetaminophen, domperidone, and levodro-
propizine, skin rash, angioedema and anaphylaxis were developed immediately. 
As she was tolerable to acetaminophen alone, we thought the culprit agent was 
maybe a levodropropizine tablet. To confirm the culprit, she underwent skin prick 
test and oral drug provocation test with the suspected one. Finally we detected le-
vodropropizine specific IgE and confirmed the specificity by inhibition enzyme-
linked immunosorbent assay (ELISA).
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INTRODUCTION
Levodropropizine is widely used peripheral acting antitussives. It suppresses 
cough through inhibition of vagal C-fiber and its neuropeptide.1 Previously report-
ed adverse drug reactions of levodropropizine were nausea, diarrhea and epigastric 
discomfort.2 Only two cases of anaphylaxis to levodropropizine were reported,3,4 
but the mechanism of levodropropizine anaphylaxis is not yet clarified. We experi-
enced a case of anaphylaxis after taking levodropropizine tablet and confirmed the 
causality with oral provocation test. Furthermore, we confirmed the presence of le-
vodropropizine specific immunoglobulin E (sIgE) with skin prick test, enzyme-
linked immunosorbent assay (ELISA) and inhibition ELISA tests. These findings 
suggest that levodropropizine can induce anaphylaxis through the IgE-mediated 
immune mechanism.
 
CASE REPORT
An 18-year old Korean woman visited outpatient clinic because of recurrent col-
lapse after taking common cold medication. She experienced generalized itching 
sensation followed by skin rash and angioedema, and collapse after common cold 
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of levodropropizine. After 2 minutes, she felt generalized 
itching sensation, and throat swelling, and skin rash was de-
veloped at anterior chest wall. We injected 1 : 1000 epineph-
rine 0.3 mL intramuscularly. She didn’t experience anaphy-
laxis. In addition, 625 mg of acetaminophen open oral 
provocation test was negative. 
We also measured levodropropizine sIgE in the patient’s 
serum by ELISA. A 96-well polystyrene plate (Costar, 
Tewksbury, MA, USA) was coated with 40 µg/mL of human 
serum albumin and incubated overnight. After blocking with 
skim milk, pure levodropropizine provided by Hyundai-
pharm.Co., Ltd. (Manufacture of Levotuss syrup®). 0.5-100 
mM 50 µL conjugated with EDC (Thermo scientific, Rock-
ford, IL, USA) 50 µL was added, and patient serum and anti-
human IgE were incubated for 1 hour each step. After wash-
ing, 1 : 1000 biotin-labeled anti-human IgE (Vector 
Laboratories Inc., Burlingame, CA, USA), Streptavidin-HRP 
(R&D systems, Minneapolis, MN, USA), TMB (Tetrameth-
ylbenzidine, KPL, Gaithersburg, MD, USA) were added to 
each well. 
The level of sIgE to levodropropizine was 0.166 optical 
density units reading at the 405-nm ultraviolet wavelength by 
an automated microplate spectrophotometer (Fig. 1A). For 
inhibition ELISA, patient serum was preincubated for 1 day 
before and being measured in the ELISA performed before. 
The results showed dose-dependent inhibition pattern: At 0.1 
M concentration, it showed complete inhibition (Fig. 1B).
We concluded that culprit of anaphylaxis was levodropropi-
zine. The patient was educated to avoid levodropropizine. 
Since now she never experienced any allergic symptoms.
medication twice before. Her recent medication included 
acetaminophen, domperidone and levodropropizine 60 mg. 
When she took a pain killer including acetaminophen, caf-
feine, or isopropylantipyrine (Geworin®, Samjinpharm 
CO., LTD, Seoul, Korea), she did not experience any aller-
gic symptoms. She had no history of any other medical ill-
ness including allergic disease. And she had no family his-
tory of allergic disease. 
Skin prick tests were found to be positive with levodro-
propizine, whereas skin prick tests and intradermal tests 
with antibiotics [Penicillin-G (Hanall biopharma, Seoul, 
Korea), Cefazolin (Yuhan Corporation, Seoul, Korea), 
Amoxacillin (Ilsung pharmaceuticals, Seoul, Korea)] were 
negative. We used levodropropizine syrup (Levotuss syr-
up®, Hyundaipharm. CO., LTD, Seoul, Korea) for skin 
prick test, started with levodropropizine 0.06 mg/mL (1 : 
100 dilution in saline) and mean diameter of wheal was 4 
mm to levodropropizine 0.06 mg/mL (10% histamine in 
phenol saline: 6 mm, 0.9% saline: negative, levodropropi-
zine 0.6 mg/mL: 5 mm, levodropropizine 6.0 mg/dL: 6.5 
mm). She had no specific IgE antibodies to antibiotics in-
cluding penicilloyl G, amoxicilloyl, ampicilloyl, and cefa-
clor by Immuno CAP® (Phadia AB, Uppsala, Sweden) 
method. Skin prick test for common inhalant allergens was 
not done. Oral provocation tests were performed to confirm 
the causative drug with 1 hour interval for each agent. We 
used levodropropizine syrup (Levotuss syrup®, 6 mg/mL, 
1/30 of recommended daily dose) and started with 6 mg. 
After taking 6 mg of levodropropizine, she had no specific 
symptom and signs for an hour. Therefore, she took 12 mg 
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Fig. 1. (A) Level of levodropropizine-specific immunoglobulin (Ig) E in healthy controls and patient serum. Control serum 0.001 OD, patient serum 0.166 OD, re-
spectively. (B) Inhibition ELISA using levodropropizine as the inhibitor. Levodropropizine showed dose-dependent inhibition pattern. At 0.1 M concentration, 
it completely inhibited the binding of specific IgE to levodropropizine-HSA conjugate. ODU, optical density unit; HSA, human serum albumin; ELISA, enzyme-
linked immunosorbent assay. 
A B
Kyung Hee Park, et al.
Yonsei Med J   http://www.eymj.org   Volume 54   Number 1   January 2013264
SA measurement. For ELISA inhibition test, we incubated 
the patient’s serum with levodropropizine as the inhibitor, 
and found that it completely inhibited the specific IgE, sug-
gesting that levodropropizine can easily form levodropropi-
zine-carrier complex through hapten process.7
In conclusion, we report a third case of anaphylaxis to le-
vodropropizine which might have been induced by IgE me-
diated immune mechanism. Therefore, we could suggest 
that levodropropizine as a candidate of culprit drug in addi-
tion to non-steroidal anti-inflammatory drugs and antibiot-
ics, when anaphylaxis occurs after taking anti-cough or 
common cold medication.
ACKNOWLEDGEMENTS
This study was supported by a grant from the grant (07072 
KFDA213) from the Korea Food & Drug Administration.
REFERENCES
1. Lavezzo A, Melillo G, Clavenna G, Omini C. Peripheral site of 
action of levodropropizine in experimentally-induced cough: role 
of sensory neuropeptides. Pulm Pharmacol 1992;5:143-7.
2. Luporini G, Barni S, Marchi E, Daffonchio L. Efficacy and safety 
of levodropropizine and dihydrocodeine on nonproductive cough in 
primary and metastatic lung cancer. Eur Respir J 1998;12:97-101.
3. Hur GY, Lee SY, Shim JJ, Park HS, Kang KH. An anaphylactic 
reaction caused by levodropropizine. Allergy 2010;65:409-10. 
4. Yoon K, Kim SH, Ahn Y. A case of levodropropizine-induced 
anaphylaxis. Korean J Asthma Allergy Clin Immunol 2011;31: 
219-22.
5. Banderali G, Riva E, Fiocchi A, Cordaro CI, Giovannini M. Effi-
cacy and tolerability of levodropropizine and dropropizine in chil-
dren with non-productive cough. J Int Med Res 1995;23:175-83.
6. Bruschi C, Crotti P, Dacosto E, Fanfulla F, Daffonchio L, Novelli-
ni R. Levodropropizine does not affect P0.1 and breathing pattern 
in healthy volunteers and patients with chronic respiratory impair-
ment. Pulm Pharmacol Ther 2003;16:231-6.
7. Torres MJ, Blanca M, Fernandez J, Romano A, Weck A, Aberer 
W, et al. Diagnosis of immediate allergic reactions to beta-lactam 
antibiotics. Allergy 2003;58:961-72.
DISCUSSION
Antitussive agents are divided into two groups by their action 
sites. Centrally acting antitussives include narcotic opioid 
(morphine, codein), non-narcotic opioid (dextromephorphan) 
and nonopioid (benproperine, zipeprol), and peripherally act-
ing cough suppressant includes benzonatate, and levodro-
propizine. Previous clinical studies showed that levodro-
propizine is as effective as centrally acting cough suppressant 
such as codein2 and dextromethorphan.5 However, levodro-
propizine has been regarded safer than centrally acting anti-
tussives in terms of central side effects such as somnolence 
and sedation.6 Therefore, it is widely given to acute or chron-
ic bronchitis patients.
Previously reported adverse drug reactions of levodropropi-
zine were nausea, vomiting, dyspepsia, diarrhea, fatigue, gen-
eral weakness, somnolence, headache, dizziness, palpitation 
and rarely allergic skin reaction. Only 2 cases of anaphylaxis 
to levodropropizine have been reported worldwide. The 
first case was 41-year-old Korean man. Intradermal test and 
oral provocation test to levodropropizine showed positive 
result and basophil histamine release test was positive which 
indicates that direct histamine release could induce levodro-
propizine anaphylaxis.3 The second case was 4-year old 
boy, and his skin prick test and oral provocation to levodro-
propizine was similarly positive. In addition, his tryptase 
level 3 hours after anaphylaxis was in upper normal range.4
In our present case, skin prick test and oral provocation 
test results were positive, and we also could detect sIgE to 
levodropropizine in patient’s serum, which means that le-
vodropropizine can induce anaphylaxis by IgE mediated 
mechanism. In addition, we performed ELISA inhibition 
test using levodropropizine as inhibitor to confirm the spec-
ificity of detected IgE, and observed dose-dependent inhibi-
tion pattern. 
Levodropropizine is a small molecule (its molecular weight 
of 236.31), therefore, it has to be conjugated to a carrier 
protein for induction of IgE immune response. We used hu-
man serum albumin as the conjugator, and used it for ELI-
